Anthem Bioscienc Q1 FY27 Earnings Call — Analysis (NSE: ANTHEM)
Q1 FY27 revenue declines 22.58% YoY to ₹418 Cr, but management points to a strong 60% order book and reiterates full-year growth in line with historical performance.
The take
Q1FY27 Revenue ₹418 Cr ( -22.58% YoY ) . New guidance — FY27 fy27 total capex ₹700 Cr . New story: Order-book-driven recovery .
Results
Revenue ₹418 Cr (-22.58% YoY); EBITDA ₹176 Cr (incl. ₹25 Cr other income), margin 39.6%; PAT ₹120 Cr (-11.67% YoY), margin 27.1%; net cash ₹1,720 Cr.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹418 Cr | -22.58% | yoy · Q1FY27 · Q1FY27 vs Q1FY26 |
| EBITDA | ₹176 Cr | none · Q1FY27 · includes ₹25 Cr other income | |
| EBITDA Margin | 39.6% | yoy · Q1FY27 · margin improvement YoY indicated by management | |
| PAT | ₹120 Cr | -11.67% | yoy · Q1FY27 · Q1FY27 vs Q1FY26 |
| PAT Margin | 27.1% | yoy · Q1FY27 · margin improvement YoY indicated by management | |
| Net Cash | ₹1,720 Cr | point_in_time · as of June 30, 2026 · Jun 30, 2026 |
Guidance
Management guides for FY27 revenue growth to match historical double-digit trajectory, with both EBITDA and PAT margins sustained, driven by 60% full-year order book visibility.
What management committed to
- FY27 revenue growth will be in line with Anthem's long-term historical double-digit growth rate. — FY27
- EBITDA and PAT margins will be sustained throughout FY27. — FY27
- Q1 FY27 is the softest quarter of the year; revenue will grow sequentially from Q2 FY27 onwards. — Q2FY27
- Unit 4 Phase 1 will be commissioned by end of FY28, adding 365 KL custom synthesis and 100 KL fermentation capacity at a total capex of ~₹1,200 Cr, split roughly 50-50 between FY27 and FY28. — 365 KL custom synthesis, 100 KL fermentation, ₹1,200 Cr capex, FY28
- FY27 capex will be close to ₹700 Cr. — ₹700 crore, FY27
- Neo Anthem (Unit 3 subsidiary) will turn break-even and may be profitable on a full-year basis in FY27. — FY27
- Semaglutide CDSCO approval expected within the next one to two quarters (i.e., by Q2-Q3 FY27). — Q3FY27
Key themes
Order-book confidence through capacity expansion and quarterly lumpiness.
How the narrative shifted
- Quarterly lumpiness is structural: Management repeatedly explains that CRDMO revenue timings depend on customer delivery schedules, global inventory rebalancing, and regulatory approvals, making quarterly results inherently uneven.
- Order-book-driven recovery: A 60% full-year order book, replenished even after Q1, provides high visibility and underpins confidence that the soft Q1 was a timing shift, with strong catch-up over the remaining three quarters.
- Capacity investment for visible pipeline: Management is pre-building Unit 4 with specific capacity additions (365 KL custom synthesis, 100 KL fermentation) to cater to growth from existing 14 commercial molecules and the 10 late-phase candidates, signalling strong demand visibility.
- Innovation defends industry-leading margins: Anthem leverages flow chemistry, bio-catalysis, and backward integration to raise material margins while simultaneously lowering cost of goods for customers, thus protecting its ~40% EBITDA margin even as capacity scales.
- Big Pharma M&A creates long-term opportunity: Acquisition of existing biotech customers by large pharma companies is framed as a positive, providing 'a foot in the door' and potential laterals that can mature over 3-4 years, although near-term impact is limited.
- GLP-1 as pending regulatory catalyst: Semaglutide is positioned as a near-term domestic opportunity awaiting only CDSCO approval; management has de-risked scale-up and sampled all major buyers, but contributes zero revenue today.
- Cost discipline and ESOP tailwind: Declining ESOP costs (₹9 Cr in FY27 vs ₹16 Cr in FY26) and tight control on employee and other expenses provide a supportive tailwind for PAT margins.
Operational commentary
- 60% order book visibility for full-year FY27, primarily from CRDMO segment, underpinning growth confidence despite a soft Q1.
- Timing-related delivery deferrals from key customers caused Q1 revenue decline; strong recovery expected from Q2 onwards with heavier scheduled deliveries in H2.
- New Big Pharma customer onboarded; multi-dimensional engagement (R&D, new projects, supply-chain diversification) with commercial contribution expected in later quarters of FY27, though final agreement is still being executed.
- One large biotech customer acquired by a Big Pharma, providing a potential long-term scale-up opportunity; no material impact on current-year numbers.
- Unit 3 (Neo Anthem) utilization ramped to 30-35% (from ~15% in FY26), driven primarily by new projects including peptide and oncology manufacturing.
- Unit 4 construction on track: Phase 1 capex of ₹1,200 Cr (365 KL custom synthesis, 100 KL fermentation) to be commissioned by end-FY28, capex broadly 50-50 across FY27 and FY28.
- Semaglutide: all scale-up trials completed; CDSCO approval expected in one to two quarters, after which commercial supply can begin; already sampled all major domestic players.
- Pipeline: 100+ early-phase active projects, 10 late-phase molecules (including two ADCs in late phase); four molecules commercialized last year expected to grow in FY27.
- ESOP cost declining: ₹9 Cr for FY27 (vs ₹16 Cr in FY26) and expected ~₹5 Cr for FY28.
- Specialty Ingredients business saw demand affected by supply-chain pressures from raw-material volatility; full-year growth still anticipated.
Analyst Q&A
Q. Why do customers defer deliveries even though the product is growing YoY?
Customers service global markets and build inventory based on regional growth projections; if uptake is slower than expected in certain regions, they reroute stock or defer fresh supplies until inventories are drawn down. Regulatory approval delays and rebalancing across geographies also cause short-term deferrals.
Q. Do you still maintain your targeted growth rate of 20% for this year?
Our growth is intact. We are not giving a guidance of any particular percentage, but historically if you look at our last 10 years' growth, we have delivered quite healthy growth rate and we'll continue to do that in this year as well.
Q. What do customers value most when choosing Anthem over other CRDMOs?
Three factors: keeping promises, bringing innovation that creates new IP for the customer, and a strong track record of regulatory compliance. Additionally, quality of manufacturing and depth of scientific talent at the shop-floor level build confidence.
Q. How is Anthem thinking about AI in its business, and could it structurally impact financials?
AI use cases are being explored in document review, predictive chemistry, and manufacturing automation. If AI increases the number of drug targets, Anthem could benefit from more discovery work. However, the current hype is ahead of real deployable use cases, and even large pharma clients remain vague. Anthem is actively seeking use cases to avoid being left behind.
Research and educational content only. Not investment advice.